InterventionsHuman trial

Orforglipron and Markers of Insulin Sensitivity and Beta-Cell Function by Prediabetes Status in Adults with Obesity: A Post Hoc Analysis of the ATTAIN-1 Trial

ADA Scientific Sessions 2026 Abstract

The paper

Carol H. Wysham, Melanie Davies, Clare Lee,

Luis-Emilio García, Adam Stefański, Yipeng Wang,

Benjamin Behrend

Spokane

ADA Scientific Sessions 2026 Abstract · 5 Jun 2026

Presented at ADA Scientific Sessions 2026 · Poster 1666-P

doi.org/10.2337/db26-1666-p

Orforglipron matches insulin glargine on cardiovascular safety
Lancet · 4 Oct 2026
A triple-target drug cut body weight by up to 19.7% in a trial
Cell Metabolism · 8 Oct 2026
Retatrutide reduces bodyweight in obesity and type 2 diabetes
Lancet · 4 Oct 2026
Survodutide reduces weight in adults with diabetes and obesity
The New England Journal of Medicine · 4 Oct 2026